Founder Directory
Built by Keitoto
Founders3
Known for these resultsRole33%Role is parsed from founder titles in yc.db. Known for 33% of these rows — the rest have no title at all, mostly 2019–2023. Those rows stay in the result and are counted as Unknown, never as No.Bio100%Bio coverage: 100% of these founders have a bio on their YC profile. Every bio-derived facet (ex-company, school, credentials, discipline) is Unknown for the rest.Ex-company0%Ex-company is matched from bios with employment context (ex-, formerly, worked at). 0% of these rows have at least one match.School100%School is matched from bios, case-sensitive for acronyms. 100% of these rows have at least one match.
- Jeff LiuFounder/CEO · FinalDoseX26Healthcare · London
- Li-Yao HuangFounder · FinalDoseX26Healthcare · London
- Steven LinFounder · FinalDoseX26Healthcare · London
FOUNDERROLEBATCHINDUSTRYLOCATIONTEAMX_url
Jeff LiuFinalDoseFounder/CEOSpring 2026HealthcareLondon, United Kingdom5—Li-Yao HuangFinalDoseFounderSpring 2026HealthcareLondon, United Kingdom5—Steven LinFinalDoseFounderSpring 2026HealthcareLondon, United Kingdom5—
Showing 1–3 of 3 founders
Jeff Liu
Founder/CEO·FinalDose
PRIMARY INFO
RoleFounder/CEO
Team size5
BatchSpring 2026
LocationLondon, United Kingdom
Company statusActive
StageEarly
BIO
CEO @ FinalDose (YC P26). Oxford PhD in Oncology. Previous startup (Vivid Dx) solved a multi-decade bottleneck in sepsis diagnostics: low biomass isolation. By overcoming this hurdle, we built the world’s fastest diagnostic system - slashing wait times from 5 days to just 30 minutes. Raised $15M in venture backing.
Ex-company, school and discipline below are derived from this bio. Nothing is inferred when the bio is missing.
BACKGROUND
CredentialsPhD
DisciplineResearcherKeyword match from the bio text, not a classifier.
TRACK RECORD
First YC company on record
COMPANY CONTEXT
FinalDoseProgrammable DNA drug destroying all cancers, unlocking 80% of targets
